Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data (Q30986546)

28 June 2017

1 reference

title

Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data (English)

1 reference

28 June 2017

1

Hans-Jürgen Möller

1 reference

28 June 2017

1 April 2005

1 reference

European Archives of Psychiatry and Clinical Neuroscience

28 June 2017

1 reference

28 June 2017

255

1 reference

28 June 2017

2

1 reference

28 June 2017

83-93

1 reference

https://scigraph.springernature.com/pub.10.1007/s00406-005-0580-z

28 June 2017

0 references

cites work

Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea

1 reference

https://api.crossref.org/works/10.1007%2FS00406-005-0580-Z

The pharmacological treatment of delusional depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-005-0580-Z

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-005-0580-Z

'Akinetic Depression' in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-005-0580-Z

State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics

21 January 2018

1 reference

12 December 2020

Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression

1 reference

12 December 2020

The range of therapeutic efficacy of atypical antipsychotics: a critical evaluation.

1 reference

12 December 2020

Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study

1 reference

12 December 2020

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

12 December 2020

Clozapine in the treatment of psychotic refractory depression

1 reference

12 December 2020

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

12 December 2020

Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder

1 reference

12 December 2020

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile

1 reference

12 December 2020

Suicide and schizophrenia

1 reference

12 December 2020

Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression

1 reference

12 December 2020

Olanzapine in the treatment of depressive disorders with psychotic symptoms

1 reference

12 December 2020

Prevalence and background factors of depression in first admitted schizophrenic patients

1 reference

12 December 2020

Olanzapine response in psychotic depression

1 reference

12 December 2020

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

The Causality of Depression in Schizophrenia

1 reference

12 December 2020

Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues

1 reference

12 December 2020

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

1 reference

12 December 2020

Challenges in the treatment of depression with psychotic features

1 reference

12 December 2020

'Revealed' Depression and Drug Treatment for Schizophrenia

1 reference

12 December 2020

A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features

1 reference

12 December 2020

Depression syndrome in the course of neuroleptic therapy

1 reference

12 December 2020

A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder

1 reference

12 December 2020

Amisulpride versus amineptine and placebo for the treatment of dysthymia

1 reference

12 December 2020

Depressions in schizophrenia: some observations on prevalence, etiology, and treatment.

1 reference

12 December 2020

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

12 December 2020

Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study

1 reference

12 December 2020

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

1 reference

12 December 2020

An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.

1 reference

12 December 2020

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

1 reference

12 December 2020

Risperidone in the treatment of affective illness and obsessive-compulsive disorder.

1 reference

12 December 2020

1 reference

12 December 2020

An open trial of olanzapine in the treatment of patients with psychotic depression

1 reference

12 December 2020

Depressive States Occurring During the Neuroleptic Treatment of Schizophrenia

1 reference

12 December 2020

Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome

1 reference

12 December 2020

An atypical responder to clozapine

1 reference

12 December 2020

Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up

1 reference

12 December 2020

Tranylcypromine plus risperidone for treatment-refractory major depression

1 reference

12 December 2020

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

12 December 2020

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment

1 reference

12 December 2020

Antidepressants for people with both schizophrenia and depression

1 reference

12 December 2020

Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia

1 reference

12 December 2020

Clinical management of clozapine patients in relation to efficacy and side-effects

1 reference

12 December 2020

Treatment of schizoaffective disorder and schizophrenia with mood symptoms

1 reference

12 December 2020

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

12 December 2020

Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study

1 reference

12 December 2020

The problem of post-psychotic schizophrenic depressions and their pharmacological induction. Long-term studies with fluspirilene and penfluridol and single-blind trial with fluphenazine-decanoate and flupenthixol-decanoate

1 reference

12 December 2020

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

Effects of risperidone on affective symptoms in patients with schizophrenia

1 reference

12 December 2020

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

12 December 2020

Subjective response to neuroleptics in schizophrenia

1 reference

12 December 2020

Quality of life in schizophrenia: insight and subjective response to neuroleptics.

1 reference

12 December 2020

What role do atypical antipsychotic drugs have in treatment-resistant depression?

1 reference

12 December 2020

Postpsychotic depression in schizophrenia

1 reference

12 December 2020

A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia

1 reference

12 December 2020

Prevalence of depressive symptoms early in the course of schizophrenia.

1 reference

12 December 2020

Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone

1 reference

12 December 2020

Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia

1 reference

12 December 2020

Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

1 reference

12 December 2020

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Clinical predictors of acute response with quetiapine in psychotic mood disorders

1 reference

12 December 2020

A novel augmentation strategy for treating resistant major depression

1 reference

12 December 2020

Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex

1 reference

12 December 2020

Clozapine use in diffuse Lewy body disease

1 reference

12 December 2020

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

12 December 2020

Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders

1 reference

12 December 2020

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

12 December 2020

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

1 reference

12 December 2020

Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group

1 reference

12 December 2020

Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome--a functional approach

1 reference

12 December 2020

Are atypical antipsychotic drugs also atypical antidepressants?

1 reference

12 December 2020

Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences

1 reference

12 December 2020

Severe Depressive Mood Changes Following Slow-release Intramuscular Fluphenazine Injection

1 reference

12 December 2020

Effect of Clozapine on Psychotic Depression and Parkinsonism

1 reference

12 December 2020

10.1007/S00406-005-0580-Z

Identifiers

DOI

1 reference

PubMed ID

15812601

Dimensions Publication ID

28 June 2017

0 references

1 reference

PubMed ID

15812601